| 关于本报告 | 01 | | --- | --- | | 董事长致辞 | 03 | | 关于我们 | 05 | | --- | --- | | | 9 | | 公司简介 | 05 | | 企业文化 | 07 | | 企业荣誉 | 08 | | ESG战略与治理 | 09 | | --- | --- | | | 9 | | ESG战略 | 09 | | ESG管治 | 12 | | 利益相关方沟通 | 13 | | 重要议题识别与分析 | 15 | | 更卓越的产品 | | | --- | --- | | 数智赋能 | 19 | | 创新驱动 | 23 | | 更和谐的生活 | | | --- | --- | | 合规治理 | 9 35 | | 幸福发展 | 39 | | 共赢共荣 | 48 | | 更绿色的环境 | | | --- | --- | | | Ç | | 低碳转型 | 59 | | 和谐自然 | 66 | | 循环经济 | 70 | 深圳证券交易所《上市公司自律监管指引第 17 号 —— 可持续发展报告（试行）》 全球报告倡议组织《可持续发展报告标准》（GRI Standards） | 附录 ...

证券代码：002001 证券简称：新和成 公告编号：2025-016 浙江新和成股份有限公司 关于以自有资金购买理财产品的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日召开第 九届董事会第十一次会议，审议通过《关于以自有资金购买理财产品的议案》， 同意公司及控股子公司使用最高额度不超过人民币 30 亿元的闲置自有资金购 买理财产品。具体情况如下： 一、基本情况 （一）投资目的 为提高流动资金使用效率，合理利用资金，在不影响公司正常经营业务的前 提下，公司及子公司计划使用闲置自有资金购买理财产品，投资安全性高、流动 性好的低风险投资产品，以增加公司收益，实现股东利益最大化。 （二）投资金额 公司及控股子公司使用最高额度不超过人民币 30 亿元的闲置自有资金购 买理财产品，上述最高额度内的资金可以滚动使用。 为控制风险，公司及控股子公司拟购买安全性高、流动性好的低风险理财产 品，投资期限在一年以内，不得购买以股票及其衍生品以及无担保债券为投资标 的银行理财产品。 （四）投资期限 单 ...

关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开的基本情况 证券代码：002001 证券简称：新和成 公告编号：2025-018 浙江新和成股份有限公司 2、股东大会召集人：公司董事会 3、会议召开的合法性、合规性情况：经公司第九届董事会第十一次会议审 议通过，决定召开2024年年度股东大会，召集程序符合有关法律、行政法规、部 门规章、规范性文件和公司章程的规定。 4、会议召开的方式和时间： （1）会议召开方式：现场表决与网络投票相结合的方式 （2）现场会议召开时间：2025 年 5 月 8 日（星期四）14:30。 （3）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 5 月 8 日 9:15—9:25、9:30－11:30 和 13:00－15:00；通过深圳证 券交易所互联网投票系统投票的具体时间为：2025 年 5 月 8 日 9:15 至 15:00 的 任意时间。 5、股权登记日：2025 年 4 月 29 日。 6、会议出席对象： （1）截至 2025 年 4 ...

证券代码：002001 证券简称：新和成 公告编号：2025-007 浙江新和成股份有限公司 第九届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）第九届监事会第七次会议于 2025 年 4 月 1 日以电子邮件方式发出会议通知，于 2025 年 4 月 11 日在公司总 部会议室召开。应出席监事五名，实际出席五名。本次会议出席人数、召开程序、 议事内容均符合《公司法》和《公司章程》的规定。会议由监事会主席吕国锋先 生主持，经表决形成决议如下： 一、会议以 5 票同意，0 票反对，0 票弃权审议通过《2024 年度监事会工作 报告》，该议案尚需提交股东大会审议。 全文详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）刊登的公告。 二、会议以 5 票同意，0 票反对，0 票弃权审议通过《2024 年年度报告及摘 要》，该议案尚需提交股东大会审议。 《 2024 年 年 度 报 告 》 全 文 详 见 公 司 同 日 在 巨 潮 资 讯 网 （http://www.cni ...

证券代码：002001 证券简称：新和成 公告编号：2025-006 浙江新和成股份有限公司 第九届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）第九届董事会第十一次会议 于 2025 年 4 月 1 日以电子邮件方式发出会议通知，于 2025 年 4 月 11 日在公司 总部会议室召开，应出席董事 11 名，实际出席董事 11 名，其中董事周贵阳委托 董事石观群进行投票，独立董事季建阳委托独立董事沈玉平进行投票。公司监事 和高级管理人员列席了会议。符合《公司法》和《公司章程》的规定。会议由董 事长胡柏藩先生主持，经表决形成决议如下： 一、会议以 11 票同意，0 票反对，0 票弃权审议通过《2024 年度总经理工作 报告》。 二、会议以 11 票同意，0 票反对，0 票弃权审议通过《2024 年度董事会工作 报告》的议案，该议案尚需提交股东大会审议。公司独立董事季建阳、沈玉平、 万峰、王洋向董事会提交了独立董事述职报告，并将在公司 2024 年年度股东大 会上述职。 全文详见公司同日在巨 ...

证券代码：002001 证券简称：新和成 公告编号：2025-009 浙江新和成股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 浙江新和成股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日召开的 第九届董事会第十一次会议审议通过《2024 年度利润分配预案》，该事项尚需提 交 2024 年年度股东大会审议。 二、2024 年度利润分配预案的基本情况 1、本次利润分配方案的基本内容 经天健会计师事务所（特殊普通合伙）审计，2024 年度公司实现净利润 5,896,870,207.59 元，其中归属于母公司股东的净利润 5,868,545,988.62 元。2024 年母公司实现净利润 2,726,593,387.44 元，加上年初未分配利润 5,137,599,917.63 元，减去 2024 年度分配股利 1,383,039,756.00 元，2024 年度提取盈余公积 0 元， 经决算，2024 年末可供股东分配的利润为 6,481,153,549.07 元。 若在分配方案实 ...

Financial Performance - The company's operating revenue for 2024 reached ¥21,609,592,228.45, representing a 42.95% increase compared to ¥15,116,537,003.30 in 2023[17]. - Net profit attributable to shareholders for 2024 was ¥5,868,545,988.62, a significant increase of 117.01% from ¥2,704,238,767.54 in 2023[17]. - The net profit after deducting non-recurring gains and losses was ¥5,828,938,494.33, up 122.97% from ¥2,614,210,640.58 in the previous year[17]. - Basic earnings per share for 2024 were ¥1.91, reflecting a 119.54% increase from ¥0.87 in 2023[17]. - The company's total assets at the end of 2024 amounted to ¥42,989,132,470.97, a 9.79% increase from ¥39,156,246,864.67 at the end of 2023[17]. - The net assets attributable to shareholders increased by 18.22% to ¥29,324,997,728.95 from ¥24,804,662,320.99 in 2023[17]. - Cash flow from operating activities for 2024 was ¥7,073,064,183.33, a 38.16% increase compared to ¥5,119,370,863.32 in 2023[17]. - The weighted average return on equity rose to 21.78%, an increase of 10.54 percentage points from 11.24% in 2023[17]. Revenue Breakdown - Revenue from the pharmaceutical and chemical sector accounted for ¥19.84 billion, which is 91.82% of total revenue, with a year-on-year growth of 43.81%[59]. - The nutrition products segment generated ¥15.05 billion, making up 69.67% of total revenue, with a significant increase of 52.58% compared to the previous year[59]. - The company’s total revenue for 2024 reached ¥21.61 billion, representing a 42.95% increase compared to ¥15.12 billion in 2023[59]. - The company achieved a 54.57% increase in foreign sales, amounting to ¥12.05 billion, which represents 55.78% of total revenue[59]. Market Outlook - The global demand for methionine is projected to increase by 6.3% in 2024, with domestic demand in China expected to rise by 4.7%[28][29]. - The vitamin market in China is expected to produce approximately 420,000 tons in 2024, accounting for 85.9% of global production, with prices recovering from a low point[27]. - The revenue of the fragrance and flavor industry in China is expected to reach ¥50 billion by 2025, with significant export contributions[30]. Research and Development - The company maintained R&D investment at over 5% of revenue for several consecutive years, focusing on key technologies with strategic economic impact[47]. - The company is focusing on expanding its core technology platforms in the fine chemical industry, particularly in nutrition, flavors, and new materials[26]. - The company is advancing the development of continuous reaction and pipeline reaction technologies to enhance production efficiency and competitiveness[72]. - The company has successfully achieved the production of vitamins B5 and B12 through optimized fermentation processes, positioning itself at the forefront of green manufacturing[72]. - R&D investment reached ¥1,036,161,740.50 in 2024, marking a 16.71% increase from ¥887,801,475.02 in 2023, while the ratio of R&D investment to operating revenue decreased by 1.08 percentage points to 4.79%[74]. Environmental Compliance - The company has established a comprehensive wastewater treatment system, ensuring effective collection and incineration of wastewater to reduce emissions[185]. - The company is committed to higher environmental standards and exploring eco-friendly production methods in response to evolving environmental regulations[115]. - The company has successfully renewed pollution discharge permits for multiple subsidiaries, valid until 2029[180]. - All reported pollutants from the companies were within the regulatory limits, indicating compliance with environmental standards[182]. Governance and Management - The company emphasizes compliance and transparent information disclosure, ensuring all shareholders have equal access to information[126]. - The company has a robust organizational structure with independent operational departments, ensuring no overlap with the controlling shareholder's functions[134]. - The company has appointed independent directors with diverse backgrounds, including expertise in economics, management, and law, enhancing governance[143]. - The company has a clear performance guidance strategy for the upcoming fiscal year[148]. Employee and Shareholder Relations - The company distributed a cash dividend of 4.50 RMB per 10 shares, totaling 1,383,039,756.00 RMB (including tax) based on a share base of 3,073,421,680 shares[163]. - The company has a competitive compensation structure that includes basic salary, performance pay, and benefits, aimed at enhancing employee satisfaction and loyalty[161]. - The total remuneration for directors, supervisors, and senior management amounted to CNY 31.62 million[153]. Strategic Initiatives - The company plans to accelerate its internationalization strategy and enhance local operational capabilities to navigate macroeconomic uncertainties[110]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $200 million allocated for potential deals[117]. - The company aims to strengthen its nutrition business, focusing on integrated and market-coordinated operations to enhance product competitiveness[102].

Financial Performance - The company expects a net profit attributable to shareholders of 1.8 billion to 1.9 billion CNY for Q1 2025, representing a year-on-year increase of 107% to 118% compared to 869.62 million CNY in the same period last year [3]. - The net profit after deducting non-recurring gains and losses is also projected to be between 1.8 billion to 1.9 billion CNY, reflecting a growth of 110% to 122% from 857.47 million CNY in the previous year [3]. - Basic earnings per share are anticipated to be between 0.59 CNY and 0.62 CNY, up from 0.28 CNY per share in the same quarter last year [3]. Business Strategy - The increase in performance is attributed to higher sales volume and prices of key products in the nutrition segment compared to the previous year [5]. - The company will continue to focus on integrated, series, and collaborative development strategies, emphasizing "Chemical +" and "Biological +" main strategies [5]. - Future plans include enhancing application research and service capabilities, with a focus on nutrition products, flavors, high polymer new materials, and raw pharmaceutical materials [5]. - The company aims to strengthen its global marketing network and promote sustainable high-quality development while exploring opportunities in strategic emerging industries such as plant protection, new energy, energy conservation, and environmental protection [6]. Investment Risks - The financial data in the earnings forecast has not been audited by registered accountants, and investors are advised to pay attention to investment risks [4][7].

新和成（002001）公告，公司拟以自有资金或回购专项贷款以集中竞价交易的方式回购公司部分社会公 众股份，回购股份用于实施股权激励计划或员工持股计划。本次回购金额区间为3亿元-6亿元，回购价 格不超过人民币32元/股。按本次回购资金总额上下限人民币测算，预计回购股份区间为937.5万股-1875 万股，占公司总股本的比例区间为0.31%-0.61%。 ...